
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. is projected to achieve significant sales growth, with annual Korlym sales forecasted to increase by 19% to 26% year-over-year, reaching between $800 million and $850 million in FY2025. This growth is supported by strong underlying demand, as volume has grown over 40% in the last two quarters, indicating the company's effective market execution despite recent challenges. Furthermore, the promising results from clinical trials involving relacorilant, particularly in advanced cancer treatments, suggest a robust pipeline and potential for expansion into broader indications, reinforcing confidence in the company's growth trajectory.
Bears say
Corcept Therapeutics's stock outlook is negatively impacted by a recent Complete Response Letter (CRL) that suggests delays in the launch of relacorilant for Cushing’s Syndrome, prompting a significant reduction in the 12-month price target from $145 to $90 per diluted share. The company's stock price fell by approximately 50.4%, closing at around $35, reflecting market apprehension related to commercial distribution changes and anticipated softness in upcoming financial performance. Despite management's previous success in drug launches, the substantial drop in projected revenues and the market's reaction to news from the company raise concerns about future profitability and growth potential.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares